Previous 10 | Next 10 |
Thinly traded micro cap Mersana Therapeutics (NASDAQ: MRSN ) slumps 29% premarket on light volume in response to its public offering of 21.25M shares of common stock at $4 per share. More news on: Mersana Therapeutics, Healthcare stocks news, Stocks on the move, Read more...
CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced the pr...
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that it...
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that An...
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that An...
Gainers: vTv Therapeutics (NASDAQ: VTVT ) +169% . Cool Holdings (NASDAQ: AWSM ) +58% . Estre Ambiental (NASDAQ: ESTR ) +34% . PLx Pharma (NASDAQ: PLXP ) +31% . OPKO Health (NYSEMKT: OPK ) +30% . Quantum Corporation (NYSE: QTM ) +28% . Mersana Therapeutics (NASDAQ: MRSN ) +28% ...
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today a...
CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today a...
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Live Nation Entertainment, Inc. (NYSE:LYV), LightPath Technologies, Inc. ...
Mersana Therapeutics (MRSN) Q2 2018 Results Earnings Conference Call August 15, 2018 08:00 PM ET Executives Eva Jack - Chief Business Officer Anna Protopapas - CEO Tim Lowinger - Chief Scientific Officer Dave Spellman - CFO Analysts Jonathan Chang - Leerink Partners Jes...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...